कंपनी लोड हो रही है
Keep exploring
The themes Immix Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 अक्टू॰ 2026CBGraded C, now B
MCKMckesson Corporation4 नव॰ 2026BAGraded B, now A
CVSCVS Health Corp4 नव॰ 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 नव॰ 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 अक्टू॰ 2026CAGraded C, now A
कमाई कैसे होती है
- No product revenue
मुकाबला किनसे है
क्या बेचती है1
NXC-201
A treatment made from a patient’s own immune cells, altered to recognize BCMA on diseased cells. It is being studied mainly for relapsed or treatment-resistant AL amyloidosis.
किस पर टिका है, और क्या इसे तोड़ सकता है
कारोबार किन चीज़ों पर टिका है
- 1Immix depends on raising outside capital and receiving grant reimbursements to pay for research and clinical trials; it has no product sales.
- 2It relies on outside contract manufacturers to make its treatment candidates for studies and any future commercial use.
- 3It relies on a license from Hadasit and BIRAD for intellectual property used in NXC-201, and owes payments under that agreement.
- 4Progress depends on enrolling patients, completing clinical studies, and obtaining regulatory approval before any treatment can be sold.
क्या ग़लत हो सकता है
- 1Clinical studies may fail to show that NXC-201 is safe and effective, or regulators may decide the results are not enough to approve it.
- 2Immix has recurring losses and no product revenue, so it must secure further funding; if it cannot, it may have to delay, reduce, or stop development work.
- 3Reliance on outside manufacturers and licensed intellectual property could delay or disrupt development if suppliers fail to meet requirements or license rights are lost.
Immix Biopharma, Inc. के बारे में
Immix is developing chimeric antigen receptor T-cell (CAR-T) treatments, which use a patient’s own immune cells, changed to recognize and attack diseased cells. Its main candidate, NXC-201, is designed to target B-cell maturation antigen (BCMA) on cells involved in light-chain (AL) amyloidosis. Its U.S. study of NXC-201 had enrolled 45 patients by June 30, 2026 (high confidence). Immix has no approved medicines for sale and has not generated revenue from product sales.
- मुख्यालय
- Los Angeles, California
- स्थापना
- 2012
- कर्मचारी
- 21 (March 20, 2026, high)
- सूचीबद्ध
- Nasdaq Capital Market
- वित्त वर्ष का अंत
- December 31
Immix Biopharma, Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
